Generated: December 11, 2017
DrugPatentWatch Database Preview
Details for Patent: 6,479,500
« Back to Dashboard
Which drugs does patent 6,479,500 protect, and when does it expire?
Summary for Patent: 6,479,500
|Title:|| Agents for alleviating side effects|
|Abstract:||The present invention provides an agent for alleviating side effects caused by use of an anti-tumor agent, which contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidi nedione (1) represented by formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof exhibit an inflammatory-suppressing action in the digestive tract and advantageously alleviate diarrhea and loss of body weight concomitant with administration of a chemical for treating cancer without suppressing the anti-tumor effect. Thus, the compounds of the present invention are of great value as agents for alleviating side effects caused by use of an anti-tumor agent, which enable not only the chemotherapy to be continuedly carried out, but also the body exhaustion to be effectively prevented.|
|Inventor(s):|| Fukushima; Masakazu (Hannou, JP), Yamamoto; Noriyuki (Sayama, JP), Suzuki; Norihiko (Hidaka, JP) |
|Assignee:|| Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) |
Patent Claim Types:|
see list of patent claims
||Patented / Exclusive Use
|Taiho Oncology||LONSURF||tipiracil hydrochloride; trifluridine||TABLET;ORAL||207981-001||Sep 22, 2015||RX||Yes||No||► Subscribe||► Subscribe||► Subscribe||TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY|
|Taiho Oncology||LONSURF||tipiracil hydrochloride; trifluridine||TABLET;ORAL||207981-002||Sep 22, 2015||RX||Yes||Yes||► Subscribe||► Subscribe||► Subscribe||TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Foreign Priority and PCT Information for Patent: 6,479,500
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|Japan||11-77579||Mar 23, 1999|
|PCT Filed||March 16, 2000||PCT Application Number:||PCT/JP00/01607|
|PCT Publication Date:||September 28, 2000||PCT Publication Number:||
International Patent Family for Patent: 6,479,500
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.